Dardum: third generation cephalosporin antibiotic
Dardum is a third-generation cephalosporin antibiotic produced by Lizapharma in Italy. The active substance is cefoperazone, which is a powder for the preparation of an injection solution.
Dardum is widely used for the treatment of infections of the respiratory and urinary tract, skin and soft tissues, bones and joints, genitals, intra-abdominal infections, septicemia, as well as for the prevention of infectious postoperative complications.
Despite its effectiveness and wide range of applications, Dardum has a number of contraindications and side effects. Contraindications include hypersensitivity, liver failure, severe renal failure, pregnancy and breastfeeding. Side effects may include neutropenia, eosinophilia, hypocoagulation, renal dysfunction, nausea, diarrhea, allergic reactions and others.
In addition, Dardum may interact with other drugs, increasing their antimicrobial effect and nephrotoxicity. However, the effectiveness of Dardum may decrease when used simultaneously with chemotherapy drugs that cause bacteriostasis.
For the safe and effective use of Dardum, special instructions must be taken into account that warn of possible risks and restrictions in use. Such instructions include caution when used in patients with a history of allergies to penicillin or other cephalosporin antibiotics, in newborns and premature infants, in the elderly and senile, in alcoholics, in patients with an increased risk of bleeding, with partial biliary obstruction or with liver diseases, in breastfeeding women.
Thus, Dardum is an effective antibiotic for the treatment of a wide range of infections, but requires careful use and supervision by qualified medical personnel.